Abzena vs Catalent (Novo Holdings): CDMO Comparison
Side-by-side comparison of Abzena and Catalent (Novo Holdings) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent (Novo Holdings) has FDA inspections on record (1); Abzena does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Composite Signal Score: Catalent (Novo Holdings) 75/100 vs Abzena 64/100 — a 11-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Abzena and Catalent (Novo Holdings) qualify as ADC manufacturers; Catalent (Novo Holdings) carries the higher composite Signal Score for ADC programs in this comparison.
What to evaluate for ADC programs
Both Abzena and Catalent (Novo Holdings) qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Frequently asked: Abzena vs Catalent (Novo Holdings)
Which has the stronger FDA inspection record, Abzena or Catalent (Novo Holdings)?
Both Abzena and Catalent (Novo Holdings) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Abzena has 0 FDA inspections on record; Catalent (Novo Holdings) has 1.
Which is better for ADC manufacturing — Abzena or Catalent (Novo Holdings)?
Both Abzena and Catalent (Novo Holdings) are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Abzena carries a Signal Score of 64/100 and Catalent (Novo Holdings) carries 75/100 — a meaningful lead for Catalent (Novo Holdings). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →